Evaluation of the efficacy of an interdialytic “ethanol 40% v/v - enoxaparin 1000 U/mL” lock solution to prevent tunnelled catheter infections in chronic hemodialysis patients: a multi-centre, randomized, single blind, parallel group study
Abstract Background Tunnelled dialysis catheter (TC) infections are a major health complication and are associated with increased antibiotic consumption, hospital stays, health costs and mortality. Experimental data provide evidence that Ethenox, a mixture of enoxaparine 1000 U/mL in 40% v/v ethanol...
Main Authors: | , , , , , , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2019-04-01
|
Series: | BMC Nephrology |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s12882-019-1338-6 |
id |
doaj-29570724221a495a88a453486aa55ea6 |
---|---|
record_format |
Article |
spelling |
doaj-29570724221a495a88a453486aa55ea62020-11-25T02:54:23ZengBMCBMC Nephrology1471-23692019-04-0120111010.1186/s12882-019-1338-6Evaluation of the efficacy of an interdialytic “ethanol 40% v/v - enoxaparin 1000 U/mL” lock solution to prevent tunnelled catheter infections in chronic hemodialysis patients: a multi-centre, randomized, single blind, parallel group studyJulien Aniort0Aurélien Piraud1Mireille Adda2Bruno Perreira3Marc Bouiller4Jacques Fourcade5Abdallah Guerraoui6Emilie Kalbacher7Thierry Krumel8Hélène Leray Moragues9Damien Thibaudin10Carlos Gustavo Vela11Guillaume Vernin12Hugo Weclawiak13Lise Bernard14Anne Elisabeth Heng15Bertrand Souweine16Nephrology, Dialysis and Transplantation Department, Gabriel Montpied University HospitalNephrology, Dialysis and Transplantation Department, Gabriel Montpied University HospitalMedical Intensive Care Unit, Gabriel Montpied University HospitalBiostatistics Unit (DRCI), University Hospital of Clermont-FerrandNephrology and Dialysis Department, Emile Roux HospitalNephrology and Dialysis Department, Metropole-Savoie HospitalCalydial ViennesNephrology and Dialysis Department, Edouard Herriot University HospitalNephrology and Dialysis Department, University HospitalAIDERNephrology and Dialysis Department, University HospitalNephrology and Dialysis Department, HospitalAGDUCNephrology and Dialysis Department, Médipole Saint-Roch ClinicPharmacy department, Gabriel Montpied University HospitalNephrology, Dialysis and Transplantation Department, Gabriel Montpied University HospitalMedical Intensive Care Unit, Gabriel Montpied University HospitalAbstract Background Tunnelled dialysis catheter (TC) infections are a major health complication and are associated with increased antibiotic consumption, hospital stays, health costs and mortality. Experimental data provide evidence that Ethenox, a mixture of enoxaparine 1000 U/mL in 40% v/v ethanol, could be a promising lock solution. The aim of the study is to compare an interdialytic lock solution of Ethenox with reference lock solutions, unfractionated heparin (UFH) or citrate 4% for the prevention of TCI in hemodialysis patients. Method This study will monitor a multicentre, prospective, single blind, randomized, controlled, parallel group trial. The main inclusion criteria are patients > 18 years old with end-stage renal disease, treated with chronic hemodialysis/hemodiafiltration three times a week, with incident or prevalent non-impregnated internal jugular TCs inserted for at least 2 weeks and able to give informed consent. Exclusion criteria are TCI in the previous 4 weeks and anti-infective treatment for TCI in the previous 2 weeks. Patients will be randomized to receive either study treatment Ethenox in the intervention group or reference solutions in the control group, unfractionated heparin (UFH) or citrate 4% w/v according to usual practice. The primary outcome measure will be time to first TCIs assessed by an endpoint adjudication committee blinded to the study arm according to predefined criteria. Patients will receive the study treatment for up to 12 months. Intention-to-treat analysis of the primary endpoint will be performed with a marginal Cox proportional hazard model. Prospective power calculations indicate that the study will have 90% statistical power to detect a clinical significant two-fold increase in median infection-free survival if 200 patients are recruited into each arm over a period of 24 months. Discussion Firm evidence of the efficacy of the Ethenox lock in preventing TCI could be of major clinical benefit for patients. The results of this study will allow the development of new guidelines based on a high level of evidence. Trial registration ClinicalTrials.gov Identifier: NCT03083184, date of registration March 17 2017 and European Clinical Trials Database Identifier: EudraCT 2016-A00180-51), date of registration July 11 2016.http://link.springer.com/article/10.1186/s12882-019-1338-6TunnelledHemodialysisCatheterInfectionEthanolLow molecular weight heparin |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Julien Aniort Aurélien Piraud Mireille Adda Bruno Perreira Marc Bouiller Jacques Fourcade Abdallah Guerraoui Emilie Kalbacher Thierry Krumel Hélène Leray Moragues Damien Thibaudin Carlos Gustavo Vela Guillaume Vernin Hugo Weclawiak Lise Bernard Anne Elisabeth Heng Bertrand Souweine |
spellingShingle |
Julien Aniort Aurélien Piraud Mireille Adda Bruno Perreira Marc Bouiller Jacques Fourcade Abdallah Guerraoui Emilie Kalbacher Thierry Krumel Hélène Leray Moragues Damien Thibaudin Carlos Gustavo Vela Guillaume Vernin Hugo Weclawiak Lise Bernard Anne Elisabeth Heng Bertrand Souweine Evaluation of the efficacy of an interdialytic “ethanol 40% v/v - enoxaparin 1000 U/mL” lock solution to prevent tunnelled catheter infections in chronic hemodialysis patients: a multi-centre, randomized, single blind, parallel group study BMC Nephrology Tunnelled Hemodialysis Catheter Infection Ethanol Low molecular weight heparin |
author_facet |
Julien Aniort Aurélien Piraud Mireille Adda Bruno Perreira Marc Bouiller Jacques Fourcade Abdallah Guerraoui Emilie Kalbacher Thierry Krumel Hélène Leray Moragues Damien Thibaudin Carlos Gustavo Vela Guillaume Vernin Hugo Weclawiak Lise Bernard Anne Elisabeth Heng Bertrand Souweine |
author_sort |
Julien Aniort |
title |
Evaluation of the efficacy of an interdialytic “ethanol 40% v/v - enoxaparin 1000 U/mL” lock solution to prevent tunnelled catheter infections in chronic hemodialysis patients: a multi-centre, randomized, single blind, parallel group study |
title_short |
Evaluation of the efficacy of an interdialytic “ethanol 40% v/v - enoxaparin 1000 U/mL” lock solution to prevent tunnelled catheter infections in chronic hemodialysis patients: a multi-centre, randomized, single blind, parallel group study |
title_full |
Evaluation of the efficacy of an interdialytic “ethanol 40% v/v - enoxaparin 1000 U/mL” lock solution to prevent tunnelled catheter infections in chronic hemodialysis patients: a multi-centre, randomized, single blind, parallel group study |
title_fullStr |
Evaluation of the efficacy of an interdialytic “ethanol 40% v/v - enoxaparin 1000 U/mL” lock solution to prevent tunnelled catheter infections in chronic hemodialysis patients: a multi-centre, randomized, single blind, parallel group study |
title_full_unstemmed |
Evaluation of the efficacy of an interdialytic “ethanol 40% v/v - enoxaparin 1000 U/mL” lock solution to prevent tunnelled catheter infections in chronic hemodialysis patients: a multi-centre, randomized, single blind, parallel group study |
title_sort |
evaluation of the efficacy of an interdialytic “ethanol 40% v/v - enoxaparin 1000 u/ml” lock solution to prevent tunnelled catheter infections in chronic hemodialysis patients: a multi-centre, randomized, single blind, parallel group study |
publisher |
BMC |
series |
BMC Nephrology |
issn |
1471-2369 |
publishDate |
2019-04-01 |
description |
Abstract Background Tunnelled dialysis catheter (TC) infections are a major health complication and are associated with increased antibiotic consumption, hospital stays, health costs and mortality. Experimental data provide evidence that Ethenox, a mixture of enoxaparine 1000 U/mL in 40% v/v ethanol, could be a promising lock solution. The aim of the study is to compare an interdialytic lock solution of Ethenox with reference lock solutions, unfractionated heparin (UFH) or citrate 4% for the prevention of TCI in hemodialysis patients. Method This study will monitor a multicentre, prospective, single blind, randomized, controlled, parallel group trial. The main inclusion criteria are patients > 18 years old with end-stage renal disease, treated with chronic hemodialysis/hemodiafiltration three times a week, with incident or prevalent non-impregnated internal jugular TCs inserted for at least 2 weeks and able to give informed consent. Exclusion criteria are TCI in the previous 4 weeks and anti-infective treatment for TCI in the previous 2 weeks. Patients will be randomized to receive either study treatment Ethenox in the intervention group or reference solutions in the control group, unfractionated heparin (UFH) or citrate 4% w/v according to usual practice. The primary outcome measure will be time to first TCIs assessed by an endpoint adjudication committee blinded to the study arm according to predefined criteria. Patients will receive the study treatment for up to 12 months. Intention-to-treat analysis of the primary endpoint will be performed with a marginal Cox proportional hazard model. Prospective power calculations indicate that the study will have 90% statistical power to detect a clinical significant two-fold increase in median infection-free survival if 200 patients are recruited into each arm over a period of 24 months. Discussion Firm evidence of the efficacy of the Ethenox lock in preventing TCI could be of major clinical benefit for patients. The results of this study will allow the development of new guidelines based on a high level of evidence. Trial registration ClinicalTrials.gov Identifier: NCT03083184, date of registration March 17 2017 and European Clinical Trials Database Identifier: EudraCT 2016-A00180-51), date of registration July 11 2016. |
topic |
Tunnelled Hemodialysis Catheter Infection Ethanol Low molecular weight heparin |
url |
http://link.springer.com/article/10.1186/s12882-019-1338-6 |
work_keys_str_mv |
AT julienaniort evaluationoftheefficacyofaninterdialyticethanol40vvenoxaparin1000umllocksolutiontopreventtunnelledcatheterinfectionsinchronichemodialysispatientsamulticentrerandomizedsingleblindparallelgroupstudy AT aurelienpiraud evaluationoftheefficacyofaninterdialyticethanol40vvenoxaparin1000umllocksolutiontopreventtunnelledcatheterinfectionsinchronichemodialysispatientsamulticentrerandomizedsingleblindparallelgroupstudy AT mireilleadda evaluationoftheefficacyofaninterdialyticethanol40vvenoxaparin1000umllocksolutiontopreventtunnelledcatheterinfectionsinchronichemodialysispatientsamulticentrerandomizedsingleblindparallelgroupstudy AT brunoperreira evaluationoftheefficacyofaninterdialyticethanol40vvenoxaparin1000umllocksolutiontopreventtunnelledcatheterinfectionsinchronichemodialysispatientsamulticentrerandomizedsingleblindparallelgroupstudy AT marcbouiller evaluationoftheefficacyofaninterdialyticethanol40vvenoxaparin1000umllocksolutiontopreventtunnelledcatheterinfectionsinchronichemodialysispatientsamulticentrerandomizedsingleblindparallelgroupstudy AT jacquesfourcade evaluationoftheefficacyofaninterdialyticethanol40vvenoxaparin1000umllocksolutiontopreventtunnelledcatheterinfectionsinchronichemodialysispatientsamulticentrerandomizedsingleblindparallelgroupstudy AT abdallahguerraoui evaluationoftheefficacyofaninterdialyticethanol40vvenoxaparin1000umllocksolutiontopreventtunnelledcatheterinfectionsinchronichemodialysispatientsamulticentrerandomizedsingleblindparallelgroupstudy AT emiliekalbacher evaluationoftheefficacyofaninterdialyticethanol40vvenoxaparin1000umllocksolutiontopreventtunnelledcatheterinfectionsinchronichemodialysispatientsamulticentrerandomizedsingleblindparallelgroupstudy AT thierrykrumel evaluationoftheefficacyofaninterdialyticethanol40vvenoxaparin1000umllocksolutiontopreventtunnelledcatheterinfectionsinchronichemodialysispatientsamulticentrerandomizedsingleblindparallelgroupstudy AT heleneleraymoragues evaluationoftheefficacyofaninterdialyticethanol40vvenoxaparin1000umllocksolutiontopreventtunnelledcatheterinfectionsinchronichemodialysispatientsamulticentrerandomizedsingleblindparallelgroupstudy AT damienthibaudin evaluationoftheefficacyofaninterdialyticethanol40vvenoxaparin1000umllocksolutiontopreventtunnelledcatheterinfectionsinchronichemodialysispatientsamulticentrerandomizedsingleblindparallelgroupstudy AT carlosgustavovela evaluationoftheefficacyofaninterdialyticethanol40vvenoxaparin1000umllocksolutiontopreventtunnelledcatheterinfectionsinchronichemodialysispatientsamulticentrerandomizedsingleblindparallelgroupstudy AT guillaumevernin evaluationoftheefficacyofaninterdialyticethanol40vvenoxaparin1000umllocksolutiontopreventtunnelledcatheterinfectionsinchronichemodialysispatientsamulticentrerandomizedsingleblindparallelgroupstudy AT hugoweclawiak evaluationoftheefficacyofaninterdialyticethanol40vvenoxaparin1000umllocksolutiontopreventtunnelledcatheterinfectionsinchronichemodialysispatientsamulticentrerandomizedsingleblindparallelgroupstudy AT lisebernard evaluationoftheefficacyofaninterdialyticethanol40vvenoxaparin1000umllocksolutiontopreventtunnelledcatheterinfectionsinchronichemodialysispatientsamulticentrerandomizedsingleblindparallelgroupstudy AT anneelisabethheng evaluationoftheefficacyofaninterdialyticethanol40vvenoxaparin1000umllocksolutiontopreventtunnelledcatheterinfectionsinchronichemodialysispatientsamulticentrerandomizedsingleblindparallelgroupstudy AT bertrandsouweine evaluationoftheefficacyofaninterdialyticethanol40vvenoxaparin1000umllocksolutiontopreventtunnelledcatheterinfectionsinchronichemodialysispatientsamulticentrerandomizedsingleblindparallelgroupstudy |
_version_ |
1724721491214336000 |